Kidney disease is common: roughly 1 in 7 American adults—about 35.5 million people—has chronic kidney disease (CKD), and most of them do not know it. The CDC's population surveys put diagnosed and undiagnosed CKD together at approximately 14 percent of adults, with risk rising steeply after age 60.
That single statistic hides a more interesting story. "Common" depends on which kidney disease you mean, how you define it, and whose kidneys you are counting. Acute kidney injury (AKI) is common in hospitals but rare in the community. Kidney failure requiring dialysis is uncommon but extremely consequential. Genetic and immune forms of kidney disease are individually rare yet collectively account for a meaningful share of cases in younger people. This explainer walks through the mechanisms that drive those numbers, where the thresholds come from, and what the prevalence figures can and cannot tell you.
The filtration mechanism that defines prevalence
Each kidney contains roughly a million nephrons, and each nephron is a capillary tuft (the glomerulus) feeding into a tubule. Blood pressure pushes plasma across the glomerular filter; the tubule then reclaims most of the water and solutes and secretes waste. CKD means this architecture has been losing functional nephrons for months to years.
The key concept is reserve. You can lose a large fraction of nephron mass before serum creatinine—the standard blood marker—moves outside the reference range. The remaining nephrons compensate by increasing single-nephron filtration, which keeps total filtration apparently normal for a while. That compensation is why CKD is silent early: symptoms track function loss with a long lag.
Prevalence figures are therefore threshold artifacts. Change the cutoff for estimated glomerular filtration rate (eGFR) or the albumin-to-creatinine ratio (ACR), and the count of "cases" shifts substantially. The widely cited 14 percent comes from applying the Kidney Disease: Improving Global Outcomes (KDIGO) definition—markers of kidney damage or eGFR below 60 for at least three months—to population survey data. Loosen the ACR cutoff and millions more adults qualify; tighten it and prevalence falls.
Age matters mechanically too. Nephron mass and filtration decline with age even in people without disease, so an eGFR of 55 in an 80-year-old is not the same event as an eGFR of 55 in a 40-year-old. Prevalence curves steepen after 60 largely because of this biology plus accumulated exposure to hypertension and diabetes.
Quantified context: what the surveys actually measure
The CDC's Chronic Kidney Disease Surveillance System draws on the National Health and Nutrition Examination Survey, which measures both serum creatinine and albuminuria in a nationally representative sample. From those data, about 1 in 7 adults meets CKD criteria, and roughly 9 in 10 of those people are unaware of it. Awareness is better at lower eGFR—people with advanced disease usually know—and poor at earlier stages.
Stage distribution is heavily weighted toward early disease. Stage 3 (eGFR 30–59) is the most populated category among adults, followed by stages 1 and 2 (normal or near-normal eGFR with albuminuria or other damage markers). Stages 4 and 5 (eGFR below 30) are a small fraction of total CKD but dominate costs and clinical attention. This skew explains why "CKD affects 35 million Americans" and "fewer than 1 million are on dialysis or have a transplant" are both true: they describe different slices of the same distribution.
AKI has a separate epidemiology. Community-acquired AKI is uncommon, but hospital-acquired AKI affects a substantial share of inpatients—commonly cited figures run from about 1 in 5 to 1 in 3 hospitalized patients depending on definition and case mix. Because AKI definitions hinge on creatinine change over 48 hours or urine output over 6 hours, the count is sensitive to how often you measure. A patient whose creatinine is checked twice may never be counted.
Kidney failure with sustained treatment—dialysis or transplant—has prevalence in the range of roughly 1 in 1,000 Americans, with incidence (new cases per year) far lower. These are order-of-magnitude anchors, not precision figures; registries and survey estimates differ by methodology.
Where the thresholds come from, and why they disagree
Three definitions circulate, and they do not produce identical counts:
KDIGO CKD: eGFR below 60, or a damage marker such as ACR of 30 mg/g or higher, sustained beyond three months. Diabetes-specific albuminuria: ACR of 30 mg/g or higher on two of three samples over three to six months, used to stage diabetic kidney disease. AKI (KDIGO): creatinine rise of 0.3 mg/dL or more within 48 hours, or 1.5 times baseline within seven days, or urine output below 0.5 mL/kg/h for six hours.
The reconciliation is straightforward once you see the logic. The CKD definition is a chronicity rule: it requires persistence, which is why a single abnormal lab does not make a diagnosis. The diabetes rule is a confirmation rule: it requires repeat sampling to exclude transient albuminuria from exercise, fever, or urinary infection. The AKI rule is an acuity rule: it deliberately captures short-window change, which is why it flags events that would never meet CKD criteria.
A practical consequence: a person can meet AKI criteria in the hospital, recover, and never appear in CKD prevalence statistics. Conversely, a person with stable ACR of 40 mg/g and eGFR of 90 has CKD by KDIGO but would not register if you screened on eGFR alone. Most "how common" numbers are built on the broader definition, which is one reason they look large.
The comparison that matters: CKD versus other chronic conditions
| Condition | Approximate adult US prevalence | Typical detection pattern | Dominant driver |
|---|---|---|---|
| Chronic kidney disease (all stages) | About 14% of adults | Mostly silent until late | Diabetes and hypertension |
| Diagnosed diabetes | About 11–12% of adults | Often symptomatic or screened | Metabolic |
| Hypertension | About 45–48% of adults | Often silent | Vascular |
| Heart failure | A few percent of adults | Symptomatic | Cardiac and vascular |
| Treated kidney failure (dialysis/transplant) | Well under 1% | Detected by labs | Late-stage CKD progression |
| Hospital-acquired AKI | About 20–30% of inpatients | Detected by monitoring | Acute illness, medications, ischemia |
The comparison clarifies why CKD prevalence looks high relative to dialysis prevalence: the bulk of cases are early-stage and clinically quiet. It also clarifies why CKD is frequently described as a multiplier condition—most people with CKD also have diabetes or hypertension, so its prevalence is partly a shadow of theirs. Prevalence percentages above are approximate survey-derived ranges, not fixed constants; they drift with population aging and diagnostic practice.
Counterintuitive detail: the awareness gap is not just about access
The professional caveat worth internalizing is that most people with CKD in surveys are unaware, and this is not solely an insurance or access problem. Early CKD generates no symptoms because the reserve mechanism described above masks function loss. There is no pain, no fatigue specific to the disease, and no visible sign until advanced stages bring fluid retention or anemia. Screening therefore drives detection: people tested for other reasons—diabetes monitoring, preoperative labs, hypertension management—get counted, and people never tested do not.
This has a statistical consequence that is easy to miss. Prevalence estimates from survey data are only as good as the measurements taken, and single-timepoint creatinine and albuminuria can misclassify. A person with a transiently elevated ACR from a recent illness may be counted as a case. A person with a high eGFR but reduced reserve may be missed. The 14 percent figure is a population average, not a reliable individual probability.
Edge cases that change the count
Several groups complicate the headline number.
Older adults: eGFR declines with age, so stage 3 CKD is common in people over 70 largely as a function of time. Whether age-related filtration decline should be labeled "disease" is actively debated; some clinicians argue it over-medicalizes normal aging, while others note that age-related decline still predicts cardiovascular events and medication risks.
Younger adults with genetic disease: autosomal dominant polycystic kidney disease and other inherited conditions affect a small fraction of the population but a disproportionate share of younger people with advanced CKD. These cases are individually rare, which is why they do not move national prevalence much, but they matter enormously for family screening.
Ethnic and ancestral variation: some populations have higher rates of kidney failure, driven by a mix of social determinants, access to care, and genetic variants such as APOL1 risk alleles. Prevalence of early CKD is more evenly distributed than prevalence of kidney failure, which concentrates in disadvantaged groups. The distinction matters: inequality shows up more in progression than in onset.
Acute versus chronic overlap: a person with a single AKI episode has elevated risk of later CKD, so the two categories are not independent. Counting them separately understates the cumulative burden of kidney injury over a lifetime.
Red-flag warnings
eGFR below 60 that persists on repeat testing beyond three months warrants evaluation, not watchful waiting. ACR of 30 mg/g or higher on repeated samples signals kidney damage even when eGFR is normal. Rapidly declining eGFR—a sustained drop over months—is a red flag for progressive disease regardless of absolute value. Visible blood in urine, new foamy urine, or swelling around the eyes and ankles should prompt clinical assessment. AKI during hospitalization should be documented and followed, because recovery does not erase later risk. These are screening signals, not diagnoses; interpretation requires a clinician and repeat measurements.
Practical actions with concrete thresholds
Screening is the practical lever, and the thresholds are specific. Adults with diabetes should have ACR and eGFR checked at least annually; adults with hypertension should be screened as part of routine management. People with a family history of kidney failure, prior AKI, or cardiovascular disease are reasonable candidates for periodic testing even without diabetes or hypertension.
For individuals, the actionable steps are unglamorous. Know your eGFR and ACR, not just creatinine. Keep blood pressure in the range your clinician targets—guidelines for people with CKD commonly aim below 130/80 mmHg, though targets are individualized. Manage blood glucose if diabetic. Avoid unnecessary NSAID use, especially in combination with dehydration or other kidney stressors. Ask whether any medication you take requires dose adjustment for kidney function.
For clinicians and systems, the leverage is in closing the awareness gap: flagging patients with two consecutive low eGFR values, automating ACR ordering alongside eGFR in diabetic populations, and reconciling AKI episodes into follow-up. None of these change prevalence, but they change how much of it is detected—which is the number that actually drives outcomes.
Limits of what prevalence numbers can tell you
Prevalence estimates answer "how many people meet a definition today," not "how many will progress." Most people with early CKD do not reach kidney failure; progression depends on blood pressure control, albuminuria, glycemic control, and competing risks such as cardiovascular death. A large prevalence figure therefore overstates the individual probability of dialysis and understates the population burden of cardiovascular risk that accompanies CKD.
Methodology limits are real. Survey-based estimates exclude people in institutions and rely on single-timepoint labs. Registry-based kidney failure counts are more complete but capture only treated disease. Global estimates vary widely because creatinine-based eGFR equations are calibrated to different populations and perform imperfectly across ancestries. Terms like "common" are useful for public health planning and almost useless for individual risk prediction.
The honest summary is that kidney disease is common in the sense that a large fraction of adults meet a chronic-disease definition, uncommon in the sense that treated kidney failure affects a small minority, and under-detected in the sense that most people who meet the definition do not know it. Those three facts coexist because they describe different thresholds on the same biological continuum.